JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2004) 180, 175-182       DOI: 10.1677/joe.0.1800175
© 2004 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norby, F.
Right arrow Articles by Ren, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norby, F.
Right arrow Articles by Ren, J
Journal of Endocrinology, Vol 180, Issue 1, 175-182
Copyright © 2004 by Society for Endocrinology


Articles

Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes

FL Norby, Aberle NS 2nd, J Kajstura, P Anversa, and J Ren


Diabetic cardiomyopathy is characterized by cardiac dysfunction and altered level/function of insulin-like growth factor I (IGF-I). Both endogenous and exogenous IGF-I have been shown to effectively alleviate diabetes-induced cardiac dysfunction and oxidative stress. This study was designed to examine the effect of cardiac overexpression of IGF-I on streptozotocin (STZ)-induced cardiac contractile dysfunction in mouse myocytes. Both IGF-I heterozygous transgenic mice and their wild-type FVB littermates were made diabetic with a single injection of STZ (200 mg/kg, i.p.) and maintained for 2 weeks. The following mechanical indices were evaluated in ventricular myocytes: peak shortening (PS), time-to-PS (TPS), time-to-90% relengthening (TR90) and maximal velocity of shortening/relengthening (+/- dL/dt). Intracellular Ca2+ was evaluated as resting and peak intracellular Ca2+ levels, Ca2+-induced Ca2+ release and intracellular Ca2+ decay rate (tau). STZ led to hyperglycemia in FVB and IGF-I mice. STZ treatment prolonged TPS and TR90, reduced Ca2+-induced Ca2+ release, increased resting intracellular Ca2+ levels and slowed tau associated with normal PS and +/- dL/dt. All of which, except the elevated resting intracellular Ca2+, were prevented by the IGF-I transgene. In addition, myocytes from STZ-treated FVB mice displayed an attenuated contractile response to the beta-adrenergic agonist isoproterenol, which was restored by the IGF-I transgene. Contractile response to the alpha-adrenergic agonist phenylephrine and angiotensin II was not affected by either STZ treatment or IGF-I. These results validate the beneficial role of IGF-I in diabetic cardiomyopathy, possibly due to an improved beta-adrenergic response.


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Csiszar, N. Labinskyy, V. Perez, F. A. Recchia, A. Podlutsky, P. Mukhopadhyay, G. Losonczy, P. Pacher, S. N. Austad, A. Bartke, et al.
Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1882 - H1894.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Ren, J. Duan, D. P. Thomas, X. Yang, N. Sreejayan, J. R. Sowers, A. Leri, J. Kajstura, F. Gao, and P. Anversa
IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R793 - R802.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
F. Dong, Q. Li, N. Sreejayan, J. M. Nunn, and J. Ren
Metallothionein Prevents High-Fat Diet Induced Cardiac Contractile Dysfunction: Role of Peroxisome Proliferator Activated Receptor {gamma} Coactivator 1{alpha} and Mitochondrial Biogenesis
Diabetes, September 1, 2007; 56(9): 2201 - 2212.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Li, S. Wu, S.-Y. Li, F. L. Lopez, M. Du, J. Kajstura, P. Anversa, and J. Ren
Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1398 - H1403.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
F. Dong, M. M. Taylor, W. K. Samson, and J. Ren
Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes
J Appl Physiol, September 1, 2006; 101(3): 778 - 784.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. F. Ceylan-Isik, K. H. LaCour, and J. Ren
Sex difference in cardiomyocyte function in normal and metallothionein transgenic mice: the effect of diabetes mellitus
J Appl Physiol, May 1, 2006; 100(5): 1638 - 1646.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. F. Ceylan-Isik, S. Wu, Q. Li, S.-Y. Li, and J. Ren
High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus
J Appl Physiol, January 1, 2006; 100(1): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
S.-Y. Li, C. X Fang, N. S Aberle II, B. H Ren, A. F Ceylan-Isik, and J. Ren
Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function
J. Endocrinol., September 1, 2005; 186(3): 491 - 503.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
T. Kobayashi, T. Matsumoto, and K. Kamata
IGF-I-induced enhancement of contractile response in organ-cultured aortae from diabetic rats is mediated by sustained thromboxane A2 release from endothelial cells
J. Endocrinol., August 1, 2005; 186(2): 367 - 376.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Endocrinology.